Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Core Viewpoint - Nuvectis Pharma, Inc. has initiated a Phase 1b study of NXP900 in combination with osimertinib for patients with EGFRmut+ NSCLC, aiming to address resistance to EGFR inhibitor therapy [1][5]. Group 1: NXP900 Development - NXP900 is an oral small molecule drug candidate that inhibits SRC and YES1 kinases, which are implicated in resistance to EGFR inhibitors in NSCLC [1][6]. - The Phase 1b program follows a successful Phase 1a dose escalation study and a clinical drug-drug interaction study [2]. - The ongoing single agent study evaluates NXP900's safety and clinical activity in patients with specific genetic alterations [3]. Group 2: Clinical Study Details - The Phase 1b study targets patients with unresectable, metastatic or locally advanced EGFRmut+ NSCLC who have previously responded to osimertinib [4]. - Patients with mutations known to cause resistance to osimertinib or other oncogenic drivers are excluded from the study [4]. Group 3: Company Insights - The CEO of Nuvectis expressed optimism about the potential of NXP900 to extend the benefits of osimertinib for patients who have developed resistance [5]. - The company anticipates multiple data readouts from both the single agent and combination studies in 2026 [5].